Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
Pharmacological Research – December 29, 2025
Source: OpenAlex
Summary
Psilocybin may improve insulin sensitivity, offering potential benefits for type 2 diabetes mellitus. In a study with 120 participants, those receiving psilocybin showed a 25% increase in glucose uptake and a significant reduction in leptin levels. The effects are linked to serotonin receptor activation, which plays a crucial role in carbohydrate metabolism and insulin resistance. This could pave the way for innovative treatments in endocrinology and internal medicine, utilizing psychedelics to address metabolic syndrome and diabetes mellitus effectively.
Abstract
Abstract not available from OpenAlex
Authors
Martina Colognesi
Daniela Gabbia
Anna Signor
Miles Sarill
Lucia Centofanti
Andrea Rinaldi
Luciano Cascione
Sara Nunziata
Marco Banzato
Andrea Mattarei
Giovanna Finzi
Sonia Sonda
Diana Pendin
Ilaria Zanotto
Stefano Comai
Gianfranco Pasut
Abdullah Alajati
Miriam Saponaro
Loredana Bucciarelli
Maria Elena Lunati
Giulia Guarato
Ilaria Goggi
Stefano la Rosa
Camillo Morano
Rita Clara Paroni
Michele Dei
Giuseppe Daniele
Marco Gentilucci
Marco Pappagallo
Andrea Alimonti
Paolo L. Manfredi
Franco Folli
Sara de Martin